Lung Cancer Clinical Trials in Cleveland

Showing 181-200 of 350 trials

Study of the CD40 Agonistic Monoclonal Antibody APX005M

NCT02482168

This study is a phase 1 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M in adults with solid tumors. Study is intended to establish the maximum tolerated dose and the overall safety and tolerability of APX005M in 3 different administration schedules.

CancerNSCLCMelanoma+3 more

Apexigen America, Inc.43 participantsStarted May 2015

Duarte, California, United States • Cleveland, Ohio, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPHASE1/PHASE2< 1 mile

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02439450

This study will test whether vaccination with viagenpumatucel-L combined with strategies to modulate the immune response is safe for patients with non-small cell lung adenocarcinoma or squamous cell carcinoma for incurable or metastatic disease.

Non-small Cell Lung Cancer

Heat Biologics121 participantsStarted Apr 2015

Tucson, Arizona, United States • La Jolla, California, United States • Boca Raton, Florida, United States +13 more locations

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

PBF-1129 in Patients With NSCLC

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Lung EpiCheck Biomarkers Development Study

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

The Lung Screening, Tobacco and Health Project

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Survival Prolongation by Rationale Innovative Genomics

Other Conditions in Cleveland